SCHEMBL5116717

SCHEMBL5116717

Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(-c2nnc(CC3CC3)o2)cc1

nearest known ligand 0.64

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 20/20 0.64
MAPK11 Q15759 2/20 0.64
CYP2C9 P11712 2/20 0.64
HSPB1 P04792 1/20 0.64
MAP2K1 Q02750 1/20 0.62
SGK1 O00141 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5116855 0.91 MAPK14 (0.65) MAPK14MAPK11CYP2C9HSPB1MAP2K1
SCHEMBL5110031 0.90 MAPK14 (0.65) MAPK14MAPK11CYP2C9HSPB1MAP2K1
SCHEMBL5123973 0.90 MAPK14 (0.67) MAPK14MAPK11CYP2C9HSPB1MAP2K1
SCHEMBL5108797 0.89 MAPK14 (0.64) MAPK14MAPK11CYP2C9HSPB1MAP2K1
SCHEMBL5110013 0.89 MAPK14 (0.63) MAPK14MAPK11CYP2C9HSPB1MAP2K1
SCHEMBL5116730 0.88 MAPK14 (0.62) MAPK14MAPK11CYP2C9HSPB1MAP2K1
SCHEMBL5109261 0.88 MAPK14 (0.62) MAPK14MAPK11CYP2C9HSPB1MAP2K1
SCHEMBL5116879 0.88 MAPK14 (0.59) MAPK14MAPK11CYP2C9HSPB1MAP2K1
SCHEMBL5124679 0.87 MAPK14 (0.61) MAPK14MAPK11CYP2C9HSPB1MAP2K1
SCHEMBL5113172 0.87 MAPK14 (0.61) MAPK14MAPK11CYP2C9HSPB1MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1499600-B1 HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-07-25 EP claimed
US-7425555-B2 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-09-16 US disclosed
US-7425555-B2 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-09-16 US disclosed
US-7425555-B2 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-09-16 US disclosed
EP-1499600-B1 HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-07-25 EP disclosed
US-20060089393-A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors GLAXOSMITHKLINE LLC 2006-04-27 US disclosed
EP-1499600-A1 HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-01-26 EP disclosed
WO-2003093248-A1 HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089393-A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors MAPK1, MAPK7, MAP3K1 MAPK14 8/4885MAPK11 36/4885CYP2C9 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.